The Supervision Committee of the Mercado Alternativo Bursátil (MAB) has announced the listing of EuroEspes on the Growth Companies segment of this market, following a thorough review of all the information presented by the company and after the favourable assessment report on its listing issued by MAB’s Coordination and Admission Committee. The company’s listing is scheduled to take place next Wednesday, February 16th, under the trading code EEP. Trading will be through a price setting mechanism which will match buy and sell orders by means of two daily auction periods or “fixings”, at 12 hrs and at 16 hrs. The shares will be admitted by means of a listing process. Therefore, prior to this, the company has not carried out a public share offering or subscription. The reference price used for setting the share price is €2.80 per share, the same reference price as that approved by EuroEspes’s General Shareholders Meeting, which took place on 29 November 2010. The said valuation is based on the price ranges established by the ad hoc valuation reports requested by VAHN Y CIA AUDITORS and KPMG Asesores. The term listing refers to the admission to trading of a stock when the stock can be distributed among a sufficient number of shareholders without it being necessary previously to carry out a public or private share offering. According the MAB’s regulations, if a company applies for admission without a prior share offering, the shares owned by investors who own less than 5% of the company’s share capital must represent an estimated joint value of no less than two million euros. Ernst & Young Servicios Corporativos is acting as Registered Adviser and Banco de Sabadell as Liquidity Provider. EuroEspes is a leading company in the field of Genomic Medicine and illnesses associated with the central nervous system and it has patents in nutraceutical and pharmacogenetic products.
FTSE Mondo Visione Exchanges Index:
Euroespes To Start Trading On MAB On February 16th - It Is The Thirteen Company To List On The MAB’s Growth Segment
Date 14/02/2011